Navigation Links
Glenmark Wins Two Prestigious Global Recognitions at SCRIP Awards 2011
Date:11/4/2011

MUMBAI, India, November 4, 2011 /PRNewswire/ --

SCRIP, a leading global pharmaceutical and biotech news publication, honoured Glenmark with two global recognitions, for its business excellence and innovative R & D capabilities. At a glittering ceremony in London which was attended by the Who's Who of the world pharmaceutical industry on November 3; Glenmark was presented with 'Best Company in Emerging Markets' & 'Best Overall Pipeline' recognitions for the year 2011.

"On behalf of our 8000 employees worldwide, we are honoured to receive two prestigious distinctions from a reputed organisation like Informa Healthcare, which hosts the SCRIP Awards," said Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals Limited, who received the awards on behalf of the company.  "We are specially delighted at having bagged the 'Best Overall Pipeline' distinction which is a testimony of our world-class R&D capabilities and an enormous tribute to all our research staff around the world who have committed themselves over many years to the development of our innovative pipeline," he added.

For SCRIP Awards 2011, Glenmark was the only company worldwide to be shortlisted under four categories. 'Executive of the Year - Glenn Saldanha' and 'Licensing Deal of the Year - GBR 500' were the other 2 categories, where Glenmark was nominated for this year's awards.

While announcing the nominations for Glenmark; SCRIP magazine commented:

  • "Glenmark is a leader among the emerging market companies in drug discovery and development and most of its active substances in the pipeline are first-in-Class." *1
  • "Glenmark's achievements over the year included a major deal with Sanofi in Crohn's disease, completing Phase III trials of its first novel product, crofelemer and demonstrated higher sales and profit growth."*2

* 1 SCRIP magazine issue dated Sep 23, 2011  * 2 SCRIP magazine issue dated Sep 16, 2011

About Glenmark

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India.  It is a leading player in the discovery of new molecules, both NCEs (new chemical entity) and NBEs (new biological entity).  Glenmark has eight molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis, IBD, etc.] and Pain [neuropathic pain and inflammatory pain].


'/>"/>
SOURCE Glenmark Pharmaceuticals Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pars Development and Marketing Partner, Glenmark, Enters Into A Settlement Agreement With Merck To Settle Patent Litigation Over Generic ZETIA(R)
2. Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. COPAN WASP® Lands at Prestigious Boston Medical Center
5. NxStage Board Member Dr. Barry M. Straube Honored with Prestigious Award from the American Association of Kidney Patients
6. Portrait Plasma Skin Regeneration Resurfaces at Prestigious Symposium
7. ITelagen Named to Prestigious 2011 Inc. 5000 List of Fastest-Growing Companies
8. Upsher-Smith Receives Prestigious DIANA Award for Third Year in a Row
9. Cambridge Temperature Concepts Wins Prestigious Award From the Wireless-Life Sciences Alliance for Fertility Monitor DuoFertility
10. Luminex Corporation Wins Prestigious Medical Design Excellence Award
11. Xenon Chief Scientific Officer, Dr. Michael Hayden Receives Prestigious Award for Leadership in Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... is actively feeding the Frederick area economy by obtaining investment capital for emerging ... the past 2½ years that have already resulted in more than a million ...
Breaking Medicine News(10 mins):